News & Events

Xplico participates in international congresses and events 6-8 times a year in Europe and the US, so there are plenty of opportunities to meet up with us.

We would be delighted to give you a presentation of our products and services and/or to discuss your specific needs.


Bio Europe Spring, Paris, March 23-25, 2020.

Please meet us at the 2020 Bio Europe Spring Partnering Conference in Paris, France from March 23rd to 25th. With a focus on European innovation and global collaboration, BIO-Europe Spring is the largest springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe.

(October 2019)

BIO Convention, San Diego, USA, June 8-11, 2020.

Join us at the BIO International Convention in San Diego in June 2020 and Go BEYOND. This year the Convention reflects on the passion, drive and risk-taking of an industry that consistently strives to accomplish things that others might deem impossible—an industry that goes BEYOND. The key benefits of attending the Convention are access to global biotech and pharma leaders via partnering and unparalleled networking opportunities with 17,000+ attendees.

(October 2019)

International Pharma Licensing Symposium, Brighton, United Kingdom, September 16-18, 2020.

The Pharmaceutical Licensing Group UK is hosting the XVI International Pharma Licensing Symposium (IPLS) and bringing the event to Brighton from September 16th to 18th 2020, where Xplico will also be present.

IPLS is a great opportunity for the healthcare deal-making community to come together to learn, discuss, network and partner.

(February 2020)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

It is quite impressive that we have been able to live up to this four years in a row and we express our gratitude to our customers because without their continuous support and trust this would not have been possible.


(October 2019)

The new Xplico Evaluator template is now released

Xplico proudly releases a new and enhanced version of Xplico Evaluator, our valuation tool, available for all our subscription customers.

Many things have been changed behind the scene, with only a few changes in the way the assumptions are entered. The new version can handle more advanced Deal Terms and it has more features as well as additional outputs.

(June 2019)

Publication of the Xplico Valuation Survey

In July and August 2018 Xplico conducted a survey among 600 industry professionals about valuation in the life science industry and received 79 responses. We hereby present the results of the survey.
(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

Read the full article


(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

Read the full article

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

Read the interview


(June 2018)